Multidose jeopardy: HCV transmission risk and management of acute HCV in hospital settings

Hepatology

Volumn 36, Issue 4 I, 2002, Pages 1020-1021

  Oldach, David ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; EDITORIAL; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL INFECTION; HUMAN; INFECTION RISK; PRIORITY JOURNAL; VIRAL CONTAMINATION; VIRUS TRANSMISSION;

ACUTE DISEASE; CROSS INFECTION; DISEASE OUTBREAKS; HEPATITIS C; HOSPITALS; HUMANS; INFECTION CONTROL;

EID: 0036787708     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0270-9139(02)00112-X     Document Type: Editorial

References (14)

1. Larghi A, Zuin M, Crosignani A, Ribero ML, Pipia C, Battezzati PM, Binelli G, et al. Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. Hepatology 2002;36:993-1000.
2. Widell A, Christensson B, Wiebe T, et al. Epidemiologic and molecular investigation of outbreaks of Hepatitis C Virus infection on a pediatric oncology service. Ann Int Med 1999;130:130-135.
3. Desenclos J-C, Bourdiol-Razes M, Rolin B, et al. Hepatitis C in a ward for cystic fibrosis and diabetic patients: possible transmission by spring-loaded finger-stick devices for self-monitoring of capillary blood glucose. Infect Control Hosp Epidemiol 2001;22:701-707.
4. Knoll A, Helmig M, Peters O, et al. Hepatitis C Virus transmission in a pediatric oncology ward: analysis of an outbreak and review of the literature. Lab Invest 2001;81:251-262.
5. Strathdee SA, Patrick DM, Currie S, et al. Needle exchange is not enough: lessons from the Vancouver injection drug use study. AIDS 1997;11: F59-F65.
6. Hagan H, McGough JP, Thiede H, et al. Syringe exchange and risk of hepatitis B and C viruses. Am J Epidemiol 1999;149:23-213.
7. Hagan H, Thiede H. Changes in injection risk behavior associated with participation in the Seattle needle-exchange program. J Urban Health 2000;77:369-382.
8. Seeff LB. Why is there such difficulty in defining the natural history of hepatitis C? Transfusion 2000;40:1161-1164.
9. Thimme R, Oldach D, Chang KM, et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001;194:1395-1406.
10. Lechner F, Wong DK, Dunbar R, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191:1499-1512.
11. Gerlach JT, Diepolder HM, Jung MC, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4+ T-cell response in acute hepatitis C. Gastroenterology 1999;117:933-941.
12. Gruener NH, Lechner F, Jung MC, et al. Sustained dysfunction of antiviral CD8+ T lymphoyctes after infection with hepatitis C virus. J Virol 2001;75:5550-5558.
13. Jaeckel E, Comberg M, Wederneyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452-1457.
14. Amoroso P, Rapicetta M, Tosti MEMA, et al. Correlation between virus genotypes and chronicity rate in acute hepatitis C. J Hepatol 1998;28:939-944.